Stevenage Bioscience Catalyst
Gunnels Wood Road
7 articles about Apollo Therapeutics
Apollo Therapeutics and The Institute of Cancer Research enter into collaboration for cancer drug development
Apollo Therapeutics, a portfolio biopharmaceutical company focusing on translational biology and drug development, and The Institute of Cancer Research, London, a world-leading cancer research organisation, announce they have entered into a strategic collaboration to discover and develop new cancer medicines.
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics
Avalo Therapeutics, Inc. (Nasdaq: AVTX) and Apollo Therapeutics Group Limited have entered into a worldwide, exclusive license agreement granting rights to Apollo to research, develop, manufacture and commercialize AVTX-007.
Apollo Therapeutics and King’s College London Enter Into a Strategic Collaboration
Apollo Therapeutics, a biopharmaceutical company focused on translational biology and asset-centric drug development, and King’s College London, announced the formation of a new strategic collaboration.
Apollo Therapeutics Appoints Dr. Sanjay Aggarwal as Chief Medical Officer, Opens U.S. Facility
Apollo Therapeutics today announced the appointment of Dr. Sanjay Aggarwal as the company’s chief medical officer.
Apollo Therapeutics Completes $145 Million Financing Led by Patient Square Capital to Expand and Advance Portfolio-Based Drug Development
Apollo Therapeutics, a portfolio-based biopharmaceutical company rapidly advancing potentially transformative treatments based on breakthrough discoveries, has completed a $145 million financing.
UCLB and Apollo Therapeutics secure first out-licensing deal to Deerfield, a leading U.S. healthcare investment firm
UCL Business (UCLB) and Apollo Therapeutics (Apollo), a pioneering collaboration between three global pharmaceutical companies and three UK university technology transfer offices, along with Deerfield Management Company, have completed the licensing of the first Apollo-supported project, a novel gene therapy programme developed at University College London (UCL).
Apollo Therapeutics: Dr Richard Butt Appointed CEO